[go: up one dir, main page]

WO2008138968A3 - Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg - Google Patents

Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg Download PDF

Info

Publication number
WO2008138968A3
WO2008138968A3 PCT/EP2008/055971 EP2008055971W WO2008138968A3 WO 2008138968 A3 WO2008138968 A3 WO 2008138968A3 EP 2008055971 W EP2008055971 W EP 2008055971W WO 2008138968 A3 WO2008138968 A3 WO 2008138968A3
Authority
WO
WIPO (PCT)
Prior art keywords
azabicyclo
phenothiazine
ylmethyl
oct
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/055971
Other languages
French (fr)
Other versions
WO2008138968A4 (en
WO2008138968A2 (en
Inventor
Thierry Clerc
Alain Delarue
Christophe Przybylski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of WO2008138968A2 publication Critical patent/WO2008138968A2/en
Publication of WO2008138968A3 publication Critical patent/WO2008138968A3/en
Publication of WO2008138968A4 publication Critical patent/WO2008138968A4/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a dosage form comprising 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, or at least one pharmaceutically acceptable salt of same, characterized in that it provides in a suitable form for oral administration a daily dose of 1mg to 3 mg, and to the use of same to prepare a drug to prevent and/or treat allergic disorders, most notably allergic rhinitis.
PCT/EP2008/055971 2007-05-15 2008-05-15 Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg Ceased WO2008138968A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0755075 2007-05-15
FR0755075A FR2916142A1 (en) 2007-05-15 2007-05-15 PHARMACEUTICAL FORM COMPRISING (10 - [(3S) -1-AZABICYCLO [2.2.2] OCT-3-YLMETHYL] -10H-PHENOTHIAZINE PRESENTING IN AN APPROPRIATE FORM FOR ADMINISTRATION OF A DAILY DOSE UNDER BETWEEN 1 AND 3 MG

Publications (3)

Publication Number Publication Date
WO2008138968A2 WO2008138968A2 (en) 2008-11-20
WO2008138968A3 true WO2008138968A3 (en) 2009-05-22
WO2008138968A4 WO2008138968A4 (en) 2009-07-02

Family

ID=38752476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055971 Ceased WO2008138968A2 (en) 2007-05-15 2008-05-15 Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg

Country Status (4)

Country Link
AR (1) AR066587A1 (en)
FR (1) FR2916142A1 (en)
TW (1) TW200906417A (en)
WO (1) WO2008138968A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099995A1 (en) * 2017-11-17 2019-05-23 Neurana Pharmaceuticals, Inc. Methods of administering tolperisone

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089860A1 (en) * 1982-03-05 1983-09-28 Pharmuka Laboratoires Levogyrous isomer of mequitazine, process for its preparation and pharmaceutical preparations containing it
JPH07188040A (en) * 1993-12-27 1995-07-25 Taisho Pharmaceut Co Ltd Composition for treating rhinitis
FR2772029A1 (en) * 1997-12-08 1999-06-11 Pf Medicament PROCESS FOR THE PREPARATION OF MEQUITAZINE AND NOVEL SYNTHESIS INTERMEDIATE
JP2000191536A (en) * 1998-10-20 2000-07-11 Taisho Pharmaceut Co Ltd Oral solid preparation containing mequitazine
WO2005037245A2 (en) * 2003-10-21 2005-04-28 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
JP2006096749A (en) * 2004-08-31 2006-04-13 Takeda Chem Ind Ltd Medicine composition for common cold
WO2007085652A1 (en) * 2006-01-30 2007-08-02 Pierre Fabre Medicament Use of the (s) enantiomer of mequitazine for preparing a medicament, while at the same time limiting genomic toxicity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089860A1 (en) * 1982-03-05 1983-09-28 Pharmuka Laboratoires Levogyrous isomer of mequitazine, process for its preparation and pharmaceutical preparations containing it
JPH07188040A (en) * 1993-12-27 1995-07-25 Taisho Pharmaceut Co Ltd Composition for treating rhinitis
FR2772029A1 (en) * 1997-12-08 1999-06-11 Pf Medicament PROCESS FOR THE PREPARATION OF MEQUITAZINE AND NOVEL SYNTHESIS INTERMEDIATE
JP2000191536A (en) * 1998-10-20 2000-07-11 Taisho Pharmaceut Co Ltd Oral solid preparation containing mequitazine
WO2005037245A2 (en) * 2003-10-21 2005-04-28 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
JP2006096749A (en) * 2004-08-31 2006-04-13 Takeda Chem Ind Ltd Medicine composition for common cold
WO2007085652A1 (en) * 2006-01-30 2007-08-02 Pierre Fabre Medicament Use of the (s) enantiomer of mequitazine for preparing a medicament, while at the same time limiting genomic toxicity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199538, Derwent World Patents Index; AN 1995-290311, XP002461512 *
DATABASE WPI Week 200050, Derwent World Patents Index; AN 2000-545830, XP002461514 *
DATABASE WPI Week 200628, Derwent World Patents Index; AN 2006-269425, XP002461513 *

Also Published As

Publication number Publication date
AR066587A1 (en) 2009-09-02
WO2008138968A4 (en) 2009-07-02
TW200906417A (en) 2009-02-16
WO2008138968A2 (en) 2008-11-20
FR2916142A1 (en) 2008-11-21

Similar Documents

Publication Publication Date Title
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2009026473A3 (en) Stabilized therapeutic compositions and formulations
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
MX2009007038A (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders.
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
JP2011500589A5 (en)
WO2004041190A3 (en) Composition for the treatment of macular degenration
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2008138968A3 (en) Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg
WO2005094218A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
WO2008079312A3 (en) Compositions for treatment of nasal congestion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08750306

Country of ref document: EP

Kind code of ref document: A2